AML | CHOP Research Institute

Uproleselan in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Mixed Phenotype Acute Leukemia (MPAL)

This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back (‘relapsed’) or does not respond to therapy (‘refractory’).

AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia

This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R).

Scientists Target FLT3 Protein in New Approach for High-risk Childhood Leukemias

Published on

Sep 8, 2023

in Cornerstone Blog

Immunotherapy Target in Two High-risk Childhood Leukemias

Sarah K. Tasian, MD, received a $1 million grant to further her research into a novel immunotherapy for high-risk pediatric leukemias.

FLT3 CAR T-cell Immunotherapy, Lymphatic Conference, Cellicon Valley, Pediatric Heatstroke

Published on

Jul 7, 2023

in Cornerstone Blog

In the News: Lymphatic Conference and Cellicon Valley Highlights

See highlights from the Third Annual Lymphatic Disorder Conference and Cellicon Valley ’23, and more in this week’s research news roundup.

Do RAB Proteins Play a Role in Development of Acute Myeloid Leukemia?

Published on

Jun 22, 2023

in Cornerstone Blog

Wei Tong, PhD, and colleagues found a protein interaction that appears to be a driver of hematologic malignancies.

How Does the Overexpression of MN1 Cause Acute Myeloid Leukemia?

Published on

May 19, 2021

in Cornerstone Blog

How the Overexpression of MN1 Causes Acute Myeloid Leukemia

CHOP Researchers find the novel mechanistic link by which MNI causes acute myeloid leukemia.

Cancer Immunotherapy (CAR-T)

Shifting the paradigm to treat the toughest pediatric cancers with new cell therapies that reprogram a patient's own immune system to kill cancer cells.